Menopause Neglect: How Market Bias, Workplace Policies, and Global Health Systems Undervalue Half the Population
Original framing: “The $360 Billion Market that Medicine Got Wrong for 20 Years” — Bloomberg
Recent longitudinal studies demonstrate that hormone fluctuations, sleep disruption, and cardiovascular risk converge during midlife, yet most large‑scale trials still exclude women over 50 or fail to stratify data by menopausal stage. Emerging biomarker panels and digital health monitoring can capture real‑time symptom trajectories, offering a more nuanced scientific basis for interventions. Rigorous, gender‑balanced research is essential to move beyond anecdotal evidence.
The neglect of menopause is not a simple market oversight but a symptom of entrenched gender‑age bias in biomedical research, corporate profit models, and workplace norms, reinforced by historical patterns of sidelining women's health.
Indigenous and cross‑cultural practices demonstrate that holistic, community‑based approaches can mitigate symptoms without expensive pharmaceuticals, offering a template for inclusive policy. By aligning scientific rigor with equitable R&D incentives, workplace legislation, and community‑driven health hubs, the $360 billion market can be reshaped into a catalyst for systemic health justice rather than a vehicle for profit extraction. Actors ranging from regulatory bodies and investors to labor unions and Indigenous knowledge keepers must coordinate to rewrite the narrative, turning a historically ignored life stage into a benchmark for gender‑responsive innovation.